Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO, on 20 Years of Improving Cancer Care Together: A Clinical Perspective
2015 NCCN Annual Conference
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Al B. Benson III, MD, FACP, FASCO, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the evolution of NCCN Guidelines, which are available free online, and the components that make them effective: a multidisciplinary approach, the participation of patient advocates, consistency, and affordability of the evidence.
Related Videos
Kenneth C. Anderson, MD
Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.
Anthony J. Olszanski, RPh, MD
Anthony J. Olszanski, RPh, MD, of the Fox Chase Cancer Center, discusses the advances in immunotherapy generally and for melanoma in particular.
Mario E. Lacouture, MD
Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial burden, physiological pain, and potential to alter therapy. But the side effects of targeted treatments can and should be addressed.
Wui-Jin Koh, MD
Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, discusses the program to adapt NCCN guidelines to regions of the world with different resource availability. The first guideline to be adapted in this way is for cervical cancer, which is prevalent in the developing world.
Melinda Telli, MD
Melinda Telli, MD, of Stanford Cancer Institute, discusses the TNT trial for triple-negative breast cancer and the results reported at the San Antonio Breast Cancer Symposium.
